[go: up one dir, main page]

AR075047A1 - Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. - Google Patents

Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.

Info

Publication number
AR075047A1
AR075047A1 ARP100100141A ARP100100141A AR075047A1 AR 075047 A1 AR075047 A1 AR 075047A1 AR P100100141 A ARP100100141 A AR P100100141A AR P100100141 A ARP100100141 A AR P100100141A AR 075047 A1 AR075047 A1 AR 075047A1
Authority
AR
Argentina
Prior art keywords
stx2
seq
polypeptide
protein
antibody
Prior art date
Application number
ARP100100141A
Other languages
English (en)
Original Assignee
T Of Military Medicine Inc The Henry M Jackson Foundation For The Advancemen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Of Military Medicine Inc The Henry M Jackson Foundation For The Advancemen filed Critical T Of Military Medicine Inc The Henry M Jackson Foundation For The Advancemen
Publication of AR075047A1 publication Critical patent/AR075047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Composiciones que contienen los polipéptidos Stx2 de longitud no completa que incluyen el epítope del anticuerpo monoclonal 11E10. Métodos para producir anticuerpos anti-Stx2 específicos para el epítope 11E10 de la proteína Stx2. Métodos para tratar a un sujeto que está desarrollando o está en riesgo de desarrollar, una enfermedad asociada a la toxina Shiga (por ej., síndrome urémico hemolítico y enfermedades asociadas con la infeccion por E. coli y S. dysneteriae) con un polipéptido que incluye el epítope 11E10 o con un anticuerpo anti-Stx2 que se desarrollo utilizando los métodos de la solicitud. Deteccion de la Stx2 en una muestra utilizando los anticuerpos que se desarrollaron utilizando los métodos de la solicitud. Reivindicacion 1: Una composicion para estimular una respuesta inmune contra la Stx2 que comprende un vehículo aceptable para uso farmacéutico y al menos un polipéptido purificado, dicho polipéptido comprende: (i) SEC ID Ns:1; (ii) SEC ID Nss: 1 y 2; o (iii) SEC ID Nss: 1, 2, y 3; y un andamio de proteína no-Stx2, donde dicha SEC ID Ns:1, SECs ID Nss: 1 y 2 o SECs ID Nss: 1, 2, y 3 se insertan dentro de dicho andamio de la proteína no Stx2 donde dicho polipéptido tiene la antigenicidad de la Stx2. Reivindicacion 2: La composicion de la reivindicacion 1, donde dicho andamio comprende una proteína sustancialmente idéntica a la Stx1, o un fragmento de la misma. Reivindicacion 9: Un polipéptido purificado que comprende: (i) SEC ID Ns:1; (ii) SEC ID Nss; 1 y 2; o (iii) SEC ID Nos: 1, 2, y 3; y un andamio de la proteína no Stx2, donde dicha SEC ID Ns:2, SECs ID Nss: 1 y 2, o SECs ID Nss:1, 2, y 3 se insertan dentro de dicho andamio de la proteína no Stx2 y donde dicho polipéptido tiene la antigenicidad de la Stx2. Reivindicacion 20: El polipéptido purificado de cualquiera de las reivindicaciones 9 a 19, donde dicho polipéptido es toxoideado. Reivindicacion 21: Una molécula de ácido nucleico aislada que codifica cualquiera de los polipéptidos de las reivindicaciones 9 a 19. Reivindicacion 23: Un vector capaz de expresar un polipéptido, dicho vector comprende la molécula de ácido nucleico aislada de la reivindicacion 21. Reivindicacion 24: Una célula huésped que contiene el vector de la reivindicacion 23. Reivindicacion 27: Una composicion farmacéutica para inducir una respuesta inmune a la Stx2 en un sujeto, dicha composicion farmacéutica comprende cualquiera de las composiciones de las reivindicaciones 1 a 8. Reivindicacion 31: Un anticuerpo anti-Stx2, o un fragmento del mismo, que se une específicamente al epítope 11E10 de la proteína tipo 2 (Stx2) de la toxina Shiga que comprende cualquiera de los polipéptidos de las reivindicaciones 9-19, donde dicho anticuerpo inhibe la union de un anticuerpo 11E10 (ATCC 1907), anticuerpo 11E10 quimérico, o anticuerpo 11E10 humanizado a dicha proteína Stx2. Reivindicacion 38: Una composicion farmacéutica que comprende cualquiera de los anticuerpos de las reivindicaciones 31 a 37 y un vehículo aceptable para uso farmacéutico. Reivindicacion 39: Una línea celular de hibridoma que produce cualquiera de los anticuerpos de las reivindicaciones 31 a 37.
ARP100100141A 2009-01-23 2010-01-22 Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. AR075047A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14689209P 2009-01-23 2009-01-23
US21008209P 2009-03-13 2009-03-13

Publications (1)

Publication Number Publication Date
AR075047A1 true AR075047A1 (es) 2011-03-02

Family

ID=42356196

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100141A AR075047A1 (es) 2009-01-23 2010-01-22 Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.

Country Status (16)

Country Link
US (2) US8969529B2 (es)
EP (1) EP2381954B8 (es)
JP (1) JP5773886B2 (es)
KR (1) KR101832499B1 (es)
CN (1) CN102292098A (es)
AR (1) AR075047A1 (es)
AU (1) AU2010206800B2 (es)
BR (1) BRPI1007230B1 (es)
CA (1) CA2748873C (es)
CL (1) CL2011001769A1 (es)
ES (1) ES2614803T3 (es)
MX (1) MX2011007866A (es)
NZ (1) NZ593926A (es)
PE (1) PE20120425A1 (es)
RU (1) RU2011126896A (es)
WO (1) WO2010085539A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein
US9310368B1 (en) * 2012-09-28 2016-04-12 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2)
US9513287B1 (en) * 2012-09-28 2016-12-06 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of shiga toxin 2
CA2902324A1 (en) * 2013-03-12 2014-10-09 Molecular Templates, Inc. Cd20-binding immunotoxins for inducing cellular internalization and methods using same
CN103343164B (zh) * 2013-06-17 2016-05-18 武汉轻工大学 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用
RU2573924C2 (ru) * 2013-07-11 2016-01-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)
IL287490B (en) * 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN113831416A (zh) * 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
ES2856457T3 (es) 2015-02-05 2021-09-27 Molecular Templates Inc Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA2984635A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用
CN120647752B (zh) * 2025-08-19 2025-10-28 中国人民解放军军事科学院军事医学研究院 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
AR010218A1 (es) 1996-09-10 2000-06-07 Military Henry M Jackson Foundation For The Advancement Of Una familia de proteinas bacterianas multi-unidad
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
CA2328485C (en) 1998-05-20 2011-05-03 Teijin Limited Humanized antibodies that recognize verotoxin ii and cell line producing same
EP1648501B1 (en) 2003-07-21 2011-04-06 Intervet International BV Hybrid toxins comprising shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof
WO2005052158A1 (en) 2003-11-28 2005-06-09 National Research Council Of Canada Anticarcinoma antibidies and uses thereof
AU2005210695A1 (en) 2004-02-06 2005-08-18 Nymox Corporation Humanized anti-AF-20 monoclonal antibody
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
WO2006091677A1 (en) * 2005-02-22 2006-08-31 Jean Gariepy Yeast strains expressing ribosome-inactivating protein domain and method of using same
ES2532985T3 (es) 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
WO2007124133A2 (en) * 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
EP2545936A3 (en) 2006-05-31 2013-02-20 Thallion Pharmaceuticals Inc. Methods, compositions, and kits for treating Shiga toxin associated conditions
US20090258010A1 (en) 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
JP4954293B2 (ja) * 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
EP2207793A2 (en) 2007-10-08 2010-07-21 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
CN101314616B (zh) * 2008-05-30 2011-05-11 中国人民解放军第三军医大学 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用
WO2010030986A2 (en) * 2008-09-12 2010-03-18 Scarab Genomics, Llc Clean genome bactofection
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein

Also Published As

Publication number Publication date
KR20110119725A (ko) 2011-11-02
EP2381954B8 (en) 2017-01-25
NZ593926A (en) 2013-03-28
US20110318357A1 (en) 2011-12-29
JP5773886B2 (ja) 2015-09-02
EP2381954A4 (en) 2012-08-01
JP2012515551A (ja) 2012-07-12
BRPI1007230A2 (pt) 2016-02-16
WO2010085539A1 (en) 2010-07-29
AU2010206800B2 (en) 2016-06-30
US8969529B2 (en) 2015-03-03
AU2010206800A1 (en) 2011-07-28
ES2614803T3 (es) 2017-06-02
BRPI1007230B1 (pt) 2019-11-12
MX2011007866A (es) 2011-10-06
EP2381954B1 (en) 2016-11-02
CL2011001769A1 (es) 2012-08-31
CN102292098A (zh) 2011-12-21
PE20120425A1 (es) 2012-05-03
EP2381954A1 (en) 2011-11-02
RU2011126896A (ru) 2013-02-27
US20160243210A1 (en) 2016-08-25
CA2748873A1 (en) 2010-07-29
KR101832499B1 (ko) 2018-02-26
CA2748873C (en) 2017-09-12
US9801931B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
ES2914177T3 (es) Anticuerpos anti-OX40 humanizados y usos de los mismos
PE20191648A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
ES2699753T3 (es) Mimótopos peptídicos de claudina 18.2 y sus usos
Vilanova et al. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2
JP2012515551A5 (es)
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
AR095432A1 (es) Proteínas de unión a antígeno
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
CO6251322A2 (es) Polipeptidos dominios variables de anticuerpos y antagonistas
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
BRPI0911699B8 (pt) vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
BRPI0619595B8 (pt) anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
BR112022009570A2 (pt) Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica
PE20191662A1 (es) Anticuerpos anti-il-5
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
PE20230384A1 (es) Anticuerpos cd163 o proteinas de union

Legal Events

Date Code Title Description
FC Refusal